AzTrials
AzTrials

Oral BiofilmPhase 4NCT02124655

Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth.

A Phase 4 study testing Essential oils, 0.2% chlorhexidine and Sterile water in people with Oral Biofilm and Mouthwash, run by University of Santiago de Compostela at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The accumulation and maturation of oral biofilm in the gingival margin is widely recognised to be the primary aetiological factor in the development of chronic gingivitis. Based on this association, the current treatment of gingivitis is focused on biofilm disruption, which will normally include mechanical processes… Read more about this study

Who is it for?
Ages 20 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Oral Biofilm, Mouthwash, Periodontitis
What is being tested?
Essential oils, 0.2% chlorhexidine and Sterile water
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteSpain
Study dates
Sep 2012to Jun 2013
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Systemically healthy adults.
  • Minimum of 24 permanent teeth.
  • No gingivitis (Community Periodontal Index score = 0).
  • No periodontitis (Community Periodontal Index score = 0).
  • Absence of untreated caries.

Who cannot join

  • Smoker or former smoker.
  • Presence of dental prostheses.
  • Presence of orthodontic devices.
  • Antibiotic treatment or routine use of oral antiseptics in the previous 3 months.
  • Presence of any systemic disease that could alter the production or composition of saliva.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Faculty of Medicine and Dentistry of the University of Santiago de Compostela

    Santiago de Compostela, A Coruña, 15782

Other trials in Spain

About this study

Official title: Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth: a Randomised Clinical Trial.

The accumulation and maturation of oral biofilm in the gingival margin is widely recognised to be the primary aetiological factor in the development of chronic gingivitis. Based on this association, the current treatment of gingivitis is focused on biofilm disruption, which will normally include mechanical processes, both professionally and at home. However, for patients, it is not easy to achieve a proper level of plaque control. The efficient plaque control techniques are very time consuming and require a special motivation and skills for their optimum use. It was at this point where mouthwashes become important, due to the fact that they include diverse types of antimicrobial agents to complement the results of mechanical oral hygiene measures.

Chlorhexidine is considered the "gold standard" of oral antiseptics; nevertheless it has not been recommended for long periods of time due to its well-known secondary effects. All of these inconveniences have limited its acceptability among dental professionals and users; in contrast, however, are the exceptional antiseptic properties, promoting the interest of researchers in other alternative antiplaque agents. Mouthwashes containing essential oils in their formulation have received a lot of attention. Their antiplaque activity has been demonstrated in numerous clinical studies, in which they were used in conjunction with mechanical oral hygiene measures.

Read more

In order to achieve a better understanding of the clinical effects that antimicrobial agents produce in the interior of the biofilm, it is necessary to apply a methodology in which the biofilm grows directly in the interior of the oral cavity but its three dimensional structure is not distorted by manipulation.

The aim of this study was to evaluate the in situ antiplaque effect of 2 antimicrobial agents (essential oils formulation and 0.2% chlorhexidine) in the short term with a posterior analysis on "non-destructured" biofilm with Confocal Laser Scanning Microscope combined with fluorescence staining.

Read the detailed description

The volunteers wore two individualised splint which was capable of holding 6 glass disks (6 mm in diameter, 1 mm thickness); this was polished at 800 grit. . These splints are formed of 2 sheets, an internal 1 mm soft vinyl sheet where the disks are attached and an external 1 mm rigid one made of polyethylene terephtalate that is fenestrated.

  • Mouthwash protocol During the 96 hour (4 days) duration of each course of study, each volunteer wore the splints with the glass disks, withdrawing them from the oral cavity only during meals (they were stored in an opaque container in humid conditions) and to perform oral hygiene procedures, using only the mechanical removal of bacterial plaque with water, without the use of any toothpaste or mouthwash.

Using the permitted mechanical oral hygiene measures (without the splints), the volunteers performed the following protocols based on the manufacturers' instructions, with the splints in the oral cavity, during the 4 days in the morning (8.30) after breakfast and at night (22.00) after dinner:

  1. 20 ml rinses for 30 seconds with essential oils/2 times daily. ----14 days---- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily. ----14 days---- C) 20 mL rinses for 30 seconds with sterile water (negative control). Using an internet-based balanced randomisation system, indicating the mouthwash that each subject would use first, second and third, all volunteers performed the 3 rinsing cycles, with a rest period of 14 days between each test.
  • Collection of the samples of Plaque like-biofilm Sample collection was done individually at 8 am in the morning, so that the samples of each volunteer were analysed on different days. It was determined that a minimum of 10 hours should have elapsed since the last mouthwash on the previous night.

As the glass disks were removed from the splint, they were immediately immersed in 100 µL of fluorescence solution LIVE/DEAD® BacLight™ and kept in a dark chamber at room temperature for 15 minutes. Microscopic observation was performed by a single investigator who was unaware of the study design, using a Leica TCS SP2 laser scanning spectral confocal microscope (Leica Microsystems Heidelberg GmbH, Mannheim, Germany) with an HCX APOL 63x/0.9 water-immersion lens.

  • Processing of the samples of Plaque like-Biofilm Four selected fields or XYZ series in the central part of each disk were evaluated. These fields were considered representative of the whole sample after the observer's general examination. Fluorescence emission was determined in a series of XY images in which each image corresponded to each of the Z positions (depth). The optical sections were scanned in 1 µm sections from the surface of the biofilm to its base, measuring the maximum thickness of the field and subsequently the mean thickness of the biofilm of the corresponding sample. The maximum thickness of biofilm field was defined as the distance between the substrate (in perpendicular) and the peaks of the highest cell clusters. The maximum biofilm thickness of each field was divided into 3 zones or equivalent layers: outer layer (layer 1), middle layer (layer 2) and inner layer (layer 3).

The capture of the data was done with the same settings in all cases. The spatial scan mode (XYZ) and the 1024x1024 pixels scan format resolution were used. The Argon-ion and DPSS laser were used at a 13% and 78% of maximum intensity, respectively. The values for the pinhole, zoom and scan speed were 121.58 microns, 1 and 400Hz, respectively. The only values that were different depending on the sample were the offset (range between -1% to 1%) and PMT gain which was different for channel red and green, being in general terms, higher for green than for red (test and positive control), due to the fact that there was more presence of green than red signal, being for the negative control the opposite. These values were always adjusted to get a good quality capture without background noise, avoiding excessive saturation of the brightest pixels of the image. As the technician was blind to the experiment, they were advised to make the adjustments always consistent with what was seeing by the objective of the microscope, obtaining an image which was the closest as possible to reality.

Quantification of bacterial vitality in the series of XY images was determined using cytofluorographic analysis (Leica Confocal Software). In this analysis, the images of each fluorochrome were defined as "channels" (SYTO 9 occupies the green channel and propidium iodide the red channel). Square capture masks were used to measure the area occupied (µm2) by the pixels in each channel, determining the total area occupied by the biofilm and the corresponding percentage of vitality. The intensity ranges that were considered as positive signal were between 100 and 255. Determination of the mean percentage of bacterial vitality in each field required sections with a minimum area of biofilm of 250 µm2, and the mean percentage of bacterial vitality of the biofilm was calculated for the corresponding sample and for each biofilm layer.

For quantification of the percentage of surface substrate covered by the biofilm (covering grade), the cytofluorogram itself was used. From the maximum projection (superposition of all planes captured) of each of the analysed fields, the percentage of covering grade was obtained by calculating the sum of the bacterial mass (vital and non-vital) in regard to the total surface of the field (% positive within total area).

Being tested
Essential oils, 0.2% chlorhexidine, Sterile water
Keywords
Biofilms, Chlorhexidine, Microscopy, confocal, Dental plaque, Mouthwashes
Medical subject headings
Periodontitis, Dental Plaque

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Essential oilsDrug

    Also called Listerine

  • 0.2% chlorhexidineDrug

    Also called Oraldine Perio

  • Sterile waterDrug

Study groups in NCT02124655
Study groupRoleWhat they receive
Essential oils/0.2% chlorhexidine/Sterile waterExperimentalA) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
Receives: Drug: Essential oils; Drug: 0.2% chlorhexidine; Drug: Sterile water

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bacterial vitality (%)

    ratio of alive/dead bacteria.

    Measured: 10 hours after the last mouthwash

  2. Biofilm thickness (microns)

    thickness of the biofilm from the base of the substrate to the top surface of the biofilm

    Measured: 10 hours after the last mouthwash

  3. covering grade (%)

    area of the substrate that is covered by the biofilm after the 4 days of treatment

    Measured: 10 hours after the last mouthwash

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2014 (estimated)
  2. Study startSep 2012
  3. Primary completionJun 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Intervention model
Crossover
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02124655
Sponsor's protocol ID
393/2012
Status last verified
Apr 2014
First submitted
24 Apr 2014
Last updated
29 Apr 2014
Results posted
No
Data monitoring committee
No

Publications

  • Garcia-Caballero L, Quintas V, Prada-Lopez I, Seoane J, Donos N, Tomas I. Chlorhexidine substantivity on salivary flora and plaque-like biofilm: an in situ model. PLoS One. 2013 Dec 27;8(12):e83522. doi: 10.1371/journal.pone.0083522. eCollection 2013.

    PubMed 24386220
  • Quintas V, Prada-Lopez I, Prados-Frutos JC, Tomas I. In situ antimicrobial activity on oral biofilm: essential oils vs. 0.2 % chlorhexidine. Clin Oral Investig. 2015 Jan;19(1):97-107. doi: 10.1007/s00784-014-1224-3. Epub 2014 Apr 1.

    PubMed 24687247
  • Quintas V, Prada-Lopez I, Donos N, Suarez-Quintanilla D, Tomas I. Antiplaque effect of essential oils and 0.2% chlorhexidine on an in situ model of oral biofilm growth: a randomised clinical trial. PLoS One. 2015 Feb 17;10(2):e0117177. doi: 10.1371/journal.pone.0117177. eCollection 2015.

    PubMed 25689859

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Essential oils, 0.2% chlorhexidine and Sterile water in people with Oral Biofilm and Mouthwash, run by University of Santiago de Compostela at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bacterial vitality (%) (time frame: 10 hours after the last mouthwash). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02124655, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in